The company has commenced confirmatory screening of small molecule hits that can turn off the function of NR2F6 as a part of the Company's Differentiation Therapy
Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiation therapy
The concept of differentiation therapy
has been viewed as a promising and revolutionary approach for the treatment of AML and other cancers for forty years ago.
for myelodysplastic syndrome.
Thus the dramatic finding that ATRA therapy was successful in APL was the first example of differentiation therapy
in the treatment of advanced cancer.
Now in its 32nd year, the Samuel Waxman Cancer Research Foundation (SWCRF) is a unique non-profit international organization dedicated to supporting focused concept-driven research to develop targeted cancer cell-specific therapies with minimal toxicity, such as differentiation therapy
The silencing of the expression of this orphan nuclear receptor suggests that this is a logical therapeutic target for differentiation therapy
using gene silencing technology.
is based on the concept that immature leukemia progenitor cells can be forced to differentiate into a more mature or terminally differentiated phenotype by using differentiation-inducing agents.
Regarding these progresses, differentiation therapy
is also considered for treatment of other AML patients.
Now in its 32nd year, the Samuel Waxman Cancer Research Foundation (SWCRF) "Institute Without Walls" is a unique non-profit international organization dedicated to supporting focused concept-driven research to develop targeted cancer cell-specific therapies, such as differentiation therapy
Christine Ichim, the Company's Director of Molecular Therapeutics presented preclinical data regarding its DiffronC technology( a constituent of its Differentiation Therapy
Platform) at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden on June 24[sup.
Researchers from Johns Hopkins University School of Medicine reasoned that combining epigenetic therapy, entinostat, with differentiation therapy
, retinoic acid receptor beta 2 agonist (ATRA) will provide an effective combination of drugs against TNBC.